Delcath Systems (NASDAQ:DCTH) Upgraded to "Hold" at StockNews.com

Delcath Systems (NASDAQ:DCTH - Get Free Report) was upgraded by stock analysts at StockNews.com from a "sell" rating to a "hold" rating in a report released on Friday.

Several other brokerages have also recently issued reports on DCTH. Craig Hallum started coverage on shares of Delcath Systems in a research report on Friday, June 28th. They issued a "buy" rating and a $18.00 price target for the company. Stephens restated a "buy" rating on shares of Delcath Systems in a research report on Friday, October 18th. Canaccord Genuity Group restated a "buy" rating and issued a $21.00 price target on shares of Delcath Systems in a research report on Friday, October 18th. Finally, HC Wainwright restated a "buy" rating and issued a $22.00 price target on shares of Delcath Systems in a research report on Friday, October 18th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Delcath Systems presently has an average rating of "Moderate Buy" and an average price target of $21.50.

Delcath Systems Stock Performance

Shares of Delcath Systems stock traded up $0.03 during midday trading on Friday, hitting $10.68. 246,600 shares of the company traded hands, compared to its average volume of 263,134. The stock has a market cap of $296.75 million, a price-to-earnings ratio of -4.03 and a beta of 0.78. The firm's fifty day moving average price is $9.41 and its 200-day moving average price is $7.88. Delcath Systems has a 12 month low of $2.25 and a 12 month high of $11.74.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last announced its quarterly earnings results on Monday, August 5th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.12). The company had revenue of $7.77 million for the quarter, compared to the consensus estimate of $5.00 million. Delcath Systems had a negative net margin of 474.22% and a negative return on equity of 312.48%. During the same period last year, the firm posted ($0.58) earnings per share. Equities research analysts forecast that Delcath Systems will post -1.67 earnings per share for the current year.

Institutional Investors Weigh In On Delcath Systems

A number of institutional investors have recently modified their holdings of DCTH. Rosalind Advisors Inc. boosted its stake in shares of Delcath Systems by 155.1% in the 2nd quarter. Rosalind Advisors Inc. now owns 2,650,389 shares of the company's stock valued at $22,184,000 after purchasing an additional 1,611,561 shares during the last quarter. BVF Inc. IL boosted its stake in Delcath Systems by 23.1% during the first quarter. BVF Inc. IL now owns 1,202,067 shares of the company's stock worth $5,734,000 after acquiring an additional 225,918 shares in the last quarter. Shellback Capital LP bought a new position in Delcath Systems during the second quarter worth $1,353,000. Vanguard Group Inc. boosted its stake in Delcath Systems by 31.0% during the first quarter. Vanguard Group Inc. now owns 683,686 shares of the company's stock worth $3,261,000 after acquiring an additional 161,678 shares in the last quarter. Finally, Legato Capital Management LLC bought a new position in Delcath Systems during the second quarter worth $966,000. 61.12% of the stock is owned by institutional investors.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.